An independent data monitoring committee recommended stopping the MONALEESA-2 trial early as results of a pre-planned interim analysis showed the trial met the primary endpoint of progression-free survival (PFS), Novartis AG announced May 18.
MONALEESA-2 is a pivotal Phase III trial of ribociclib (LEE011), a cyclin dependent kinase inhibitor (CDK4/6), in combination with letrozole,...